Form 4: Verve Therapeutics Chief Scientific Officer Granted Stock Options and Restricted Stock Units

Troy Lister, Chief Scientific Officer of Verve Therapeutics, was granted stock options and restricted stock units on January 8, 2025, according to a recent SEC filing.

Summary

• Troy Lister, the Chief Scientific Officer of Verve Therapeutics, was granted stock options for 225,000 shares and 40,000 restricted stock units on January 8, 2025.
• The stock options have an exercise price of $6.01 per share and will vest over a period of four years, starting with 25% vesting on January 8, 2026, and the remainder vesting monthly until January 8, 2029.
• The restricted stock units will vest in three equal annual installments, beginning on April 1, 2026, with the remaining installments vesting on April 1, 2027 and April 1, 2028.

Sentiment

Score: 7

Explanation: The document reflects a standard compensation practice, indicating a positive alignment of interests between management and shareholders. It is a routine filing and does not suggest any significant positive or negative sentiment.

Positives

• The grant of stock options and restricted stock units aligns the Chief Scientific Officer's interests with those of the shareholders.
• The vesting schedule for both the options and restricted stock units encourages long-term commitment from the executive.

Industry Context

The granting of stock options and restricted stock units is a common practice in the biotechnology industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for executives in the biotech industry, often with vesting schedules to encourage long-term performance.
• The vesting schedule of 25% after one year and the remainder monthly is a fairly standard vesting schedule for stock options.
• Restricted stock units vesting over three years is also a common practice in the industry.

Stakeholder Impact

• The stock option and restricted stock unit grants may have a positive impact on shareholder value if the executive's performance leads to company growth.
• The grants incentivize the Chief Scientific Officer to remain with the company and contribute to its long-term success.

Key Dates

Keywords

stock options, restricted stock units, insider trading, executive compensation, Verve Therapeutics, VERV, equity